Effects of Electronic Cigarettes on Nicotine Concentrations (ECIG)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study will examine whether nicotine levels increase with electronic cigarettes. It will also examine whether electronic cigarettes alter lung function tests. The study will obtain preliminary data on the medical effects of electronic cigarettes, with two different nicotine flavors, tabacco and tabacco with menthol, which are available for over the counter purchase.
The elctronic cigarettes and juice used in this study is available for purchase through the internet. An investigational new drug application (IND) is not needed for this study.
| Condition | Intervention |
|---|---|
|
Health Behavior |
Other: Nicotine with Tobacco Flavor Other: Nicotine with Tobacco and Menthol Flavor |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Crossover Assignment Masking: Open Label Primary Purpose: Basic Science |
| Official Title: | Effects of Electronic Cigarettes on Nicotine Concentrations Before and 5, 10,15,20 and 30 Minutes After Use |
- Effects E-cig use on venous nicotine concentrations before and 5, 10, 15,20 and 30 minutes after use [ Time Frame: 7-10 days ] [ Designated as safety issue: No ]To determine the effects of acute E-cig use on venous nicotine concentrations 5 minutes before and 5, 10, 15, 20 and 30 minutes after 7-10 days of e-cigarette use.
- Effects of E-cig use on measures of pulmonary resistance before and 5 minutes after use [ Time Frame: 7-10 days ] [ Designated as safety issue: No ]To determine the acute effects of E-cig use before and 5 minutes after use on measures of pulmonary resistance after 7-10 days of product use.
- Comparing smoking vs. e-cigarette use [ Time Frame: 14-20 days ] [ Designated as safety issue: No ]To obtain preliminary data comparing smoking vs. e-cigarette use on 1) overall nicotine exposure as measured by cotinine; 2) nicotine cravings and on expectancies; 3) resting pulmonary function tests as measured by body plethysmography; 4) effects on pulmonary function testing with tobacco with and without menthol flavoring..
| Estimated Enrollment: | 30 |
| Study Start Date: | October 2012 |
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | October 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Nicotine with Tobacco Flavor
Electronic cigarette liquid 18mg of nicotine in a tobacco flavor solution.
|
Other: Nicotine with Tobacco and Menthol Flavor
Randomly assigned to 18mg of nicotine with tobacco and menthol flavor for 7 to 10 days and then switched to other flavor for an additional 7 to 10 days.
Other Names:
|
|
Nicotine with Tobacco and Menthol Flavor
Electronic cigarette liquid 18mg of nicotine in a tobacco and menthol flavor solution.
|
Other: Nicotine with Tobacco Flavor
Randomly assigned to 18mg of nicotine with tobacco flavor for 7 to 10 days and then switched to other flavor for an additional 7 to 10 days.
Other Names:
|
Detailed Description:
This is a randomized two-period cross-over study in which subjects who smoke greater than 10 cigarettes will be instructed to quit smoking and use either Joye (Ego C brand) with an 18 mg cartridge containing either a tobacco or tobacco mentholated flavor for one week. Prior to starting e-cig use we will collect one blood sample for nicotine/cotinine as a measure of overall nicotine expsoure. Subjects will use the devise for one week and at the end of approximately one week of use, we will assess nicotine/cotinine concentrations (before and 5, 1015,20 and 30 minutes after the onset of ECIG use), pulmonary function tests (before and 5 minutes after ECIG use), and subjective impressions of satisfaction. At the end of one week, subjects will be crossed over to the other condition and assessments will be repeated after another week of E-cigarette use.
A total of 30 smokers will be recruited from the surrounding areas via advertisements in newspapers and radio advertisements and UCHC broadcast e-mail. Posters will be placed in clinical areas to recruit from physician practices. Current smokers are being proposed for three reasons: 1) we wish to determine whether nicotine levels from e-cigarettes rise to the levels of regular cigarettes when used by regular smokers; 2) we wish to determine if there are any differences seen in pulmonary function when a person switches from regular cigarettes to e-cigarettes; 3) we wish to evaluate the level of satisfaction that regular smokers have with e-cigarettes. All of these questions will have implications for later, more extensive studies of e-cigarettes, particularly in regard to their utility as a smoking cessation modality.
Once a potential study subject calls and expresses interest in the study, preliminary inclusion criteria will be assessed over the phone. Inclusion criteria include 1) at least 18 years of age; 2) current use of at least 10 cigarettes daily; 3) willing to abstain from cigarette smoking, and substitute e-cigs, for approximately 2 weeks; 4) able to read and sign a consent form; Exclusion criteria: 1) unstable medical or psychiatric disorders as determined by the principal investigator; 2) pregnancy; 3) known hypersensitivity to nicotine or propylene glycol or menthol; 4) previous myocardial infarction (M.I.) or stroke; 5) uncontrolled hypertension [Blood pressure (BP) >160/100); 6) insulin dependent diabetes; 7) known chronic obstructive pulmonary disease (COPD) or asthma.
Eligibility| Ages Eligible for Study: | 18 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Smoking 10 cigarettes daily
- Agree to abstain from smoking and use electronic cigarettes for 2 weeks
Exclusion Criteria:
- Unstable medical or psychiatric disorders as determined by the principal investigator
- Pregnancy
- Known hypersensitivity to nicotine or propylene glycol or menthol
- Recent M. I. or stroke
- Uncontrolled hypertension (BP.>160/100)
- Insulin dependent diabetes
- Known COPD or asthma
- Alcohol or other drug abuse or dependence
Contacts and Locations| Contact: Lynn McLaughlin, R.N. | 860-679-4647 | lmclaughlin@uchc.edu |
| United States, Connecticut | |
| University of Connecticut Health Center | Recruiting |
| Farmington, Connecticut, United States, 06030-3940 | |
| Contact: Lynn McLaughlin, R.N. 860-679-4647 lmclaughlin@uchc.edu | |
| Principal Investigator: Cheryl Oncken, M.D. | |
| Sub-Investigator: Mark Litt, Ph.D. | |
| Sub-Investigator: Nausherwan K Burki, M.D. | |
| Principal Investigator: | Cheryl Oncken, M.D. | University of Connecticut Health Center |
More Information
No publications provided
| Responsible Party: | Cheryl Oncken, Professor, Department of Medicine, University of Connecticut Health Center |
| ClinicalTrials.gov Identifier: | NCT01775787 History of Changes |
| Other Study ID Numbers: | ECIG 13-002-3 |
| Study First Received: | October 12, 2012 |
| Last Updated: | January 24, 2013 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Connecticut Health Center:
|
smoking |
Additional relevant MeSH terms:
|
Menthol Nicotine Nicotine polacrilex Antipruritics Dermatologic Agents Therapeutic Uses Pharmacologic Actions Ganglionic Stimulants Autonomic Agents |
Peripheral Nervous System Agents Physiological Effects of Drugs Nicotinic Agonists Cholinergic Agonists Cholinergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Central Nervous System Stimulants Central Nervous System Agents |
ClinicalTrials.gov processed this record on May 19, 2013